Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5984 USD | +3.00% | -8.08% | -27.18% |
May. 30 | Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target | MT |
May. 13 | Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.18% | 21.92M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+2.07% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- FBRX Stock
- News Forte Biosciences, Inc.
- Forte Biosciences : Chardan Downgrades Forte Biosciences to Sell From Buy, Adjusts Price Target to $4 From $105; Shares Slide 80% Premarket